Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metamark makes Blume-Jensen CSO

This article was originally published in Clinica

Executive Summary

Personalised medicine expert Metamark Genetics has appointed Peter Blume-Jensen to the position of chief scientific officer. Dr Blume-Jensen worked from 2001 until 2008 as department head at EMD Serono and later at Merck Research Laboratories, Merck & Co. Since 2008, he worked as executive director, external scientific affairs and vice-president of Daiichi Sankyo’s Research Institute. Cambridge, Massachusetts-based Metamark is currently developing prognostic tests that enable the personalised treatment of cancer patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel